Quick answer: peptide legality by country follows one pattern almost everywhere. Approved peptide drugs such as semaglutide and tirzepatide are legal with a prescription, while unapproved “research” peptides such as BPC-157 cannot legally be sold for human use. In 2025 and 2026, at least six of the 13 jurisdictions below (the US, Canada, the UK, Australia, Thailand and the UAE) took public action against them.[1][2][3][5][12][13]
This table summarizes each country. Where we could not confirm a point from an official or reliable source, we mark it unverified. For background, see our FDA and regulation hub, the deeper guides on Canada and the EU, UK and Australia, and are peptides controlled substances?.
The two categories that matter
- Prescription peptides are approved drugs with a marketing authorization: GLP-1s, insulin analogues, tesamorelin, oxytocin and others. Their legal status is clear in each country.
- “Research” peptides are compounds such as BPC-157, TB-500, CJC-1295, ipamorelin and retatrutide (still in trials) sold online with “not for human use” labels. No country we reviewed has approved them as medicines.
Peptide legality by country: the table
| Country | Prescription peptides | “Research” peptides | Recent action or key rule |
|---|---|---|---|
| United States | Legal with prescription (products approved by FDA) | Not approved; 17 peptides, including BPC-157, sit in FDA’s withdrawn-nominations table, and GHRP-2, GHRP-6, ipamorelin and kisspeptin-10 are in Category 2 for some routes[1] | FDA’s safety-risk list current as of April 22, 2026[1] |
| Canada | Legal with prescription and an 8-digit DIN | Illegal to sell; “research use only” labels give no exemption[2] | Health Canada advisory, April 9, 2026[2] |
| United Kingdom | Prescription-only medicines | Unlicensed medicines; retatrutide “has not been authorised for use in the UK”[3] | 12,000+ counterfeit pens seized, October 14, 2026[3] |
| European Union | Need marketing authorization; injectables usually prescription-only[4] | Unauthorized medicines; enforcement and personal-import rules vary by member state | Country-level rules: check national agency |
| Australia | Schedule 4 (prescription only) | Unapproved; named in a June 19, 2026 TGA/Chief Medical Officer warning[5] | Compounded GLP-1s banned since October 1, 2024 |
| New Zealand | Prescription medicines | Unapproved medicines can only reach a patient through a prescriber under sections 25 or 29 of the Medicines Act 1981[6] | No peptide-specific Medsafe warning found: unverified |
| Japan | Prescription drugs | Unapproved; specific rules for “research” peptides: unverified | Travellers can bring up to a one-month supply of prescription medicine without an import certificate[7] |
| China | Prescription drugs (NMPA) | Status of research peptide sales: unverified | Core semaglutide patent expired March 2026; 16 companies developing generics[8] |
| India | Prescription drugs (CDSCO) | Status of research peptide sales: unverified | DCGI-approved generic semaglutide launched March 21, 2026[9] |
| Brazil | Prescription; pharmacies must keep GLP-1 prescriptions since June 23, 2025[10] | Unregistered products banned by ANVISA resolutions (product-specific) | Prescriptions valid 90 days[10] |
| Mexico | Prescription required (Article 226, General Health Law)[11] | Unregistered products subject to COFEPRIS alerts | Counterfeit semaglutide pen alert, March 26, 2026[11] |
| Thailand | GLP-1 injections became specially controlled, prescription-only drugs from September 15, 2026[12] | Unregistered peptide injections seized in September 2026[12] | Reported by Nation Thailand; Royal Gazette text not checked |
| UAE | Prescription drugs (Emirates Drug Establishment) | Unapproved; retatrutide “has not been approved for use or distribution”[13] | Action against 71 violators, July 2026[13] |
What the table tells you
1. “Research use only” is not a legal category for people. Health Canada says the label “does not make these products legal or exempt from regulatory requirements.”[2] FDA and the TGA take the same practical view. Our guide to online peptide sales legal risks explains how regulators treat these sellers.
2. Enforcement is rising, not falling. In 2026 alone: Health Canada’s peptide advisory (April), the TGA and Chief Medical Officer warning (June), the UAE action against 71 violators (July), Thailand’s seizure and new GLP-1 controls (September) and the UK’s Birmingham pen seizure (October).[2][5][13][12][3]
3. Generic semaglutide changes prices, not legal status. India and Canada now have legal generics, and China’s core patent has expired.[9][8] These are still prescription drugs. See our peptide patents and exclusivity guide for why the U.S. timeline is years later.
Country notes
United States. FDA’s list of bulk substances that may pose significant safety risks names GHRP-2, GHRP-6, ipamorelin and kisspeptin-10 in Category 2 for some compounding routes. It also lists 17 peptides whose nominations were withdrawn, including BPC-157, TB-500, epitalon, Semax and thymosin alpha-1.[1] For the timeline, see the FDA peptide ban 2026 guide and 503A vs 503B compounding.
European Union. The legal baseline is Directive 2001/83/EC: no marketing authorization, no legal sale. Injectables are usually prescription-only under Article 71.[4] But personal import rules, pharmacy compounding and penalties are national, so a single “EU” answer does not exist.
New Zealand. Medsafe’s guidance explains that an unapproved medicine can reach a patient only through an authorised prescriber, either procured for a specific patient (section 25) or supplied by a licensed importer or manufacturer to a prescriber (section 29), with supply records sent to Medsafe.[6]
Japan. The Ministry of Health, Labour and Welfare allows personal import of general prescription medicine up to a one-month supply without special procedures. More than that needs an Import Confirmation certificate. Self-injected medicines with their syringes under one month do not need one.[7]
Brazil. ANVISA voted in April 2025 to require pharmacies to retain prescriptions for semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide and lixisenatide, effective June 23, 2025.[10]
China and India. Both had core semaglutide patents expire in March 2026. In India, Dr. Reddy’s launched a semaglutide injection approved by the Drugs Controller General of India (DCGI) for type 2 diabetes on March 21, 2026, and other Indian makers followed.[9] In China, GlobalData counted 16 companies developing generic semaglutide ahead of the March 2026 patent expiry.[8] In both countries these remain prescription medicines. We could not find an official statement on online “research” peptides from either regulator.
Mexico. COFEPRIS’s March 26, 2026 alert concerned a counterfeit semaglutide 1 mg pen that contained no active ingredient. It reminded the public that the product needs a prescription under Article 226 of the General Health Law. COFEPRIS also urged people to avoid social media, online platforms and street markets for prescription drugs.[11]
Thailand. Thailand’s Public Health Ministry moved injectable GLP-1 drugs into the “specially controlled” category from September 15, 2026. That means a doctor’s prescription and a pharmacist must handle each sale. In the same month, the Thai FDA and police seized unregistered peptide injections worth more than 52 million baht.[12]
United Arab Emirates. The Emirates Drug Establishment said in July 2026 that it had acted against 71 violators marketing unapproved peptide weight-loss products. They included 14 licensed facilities and 14 social media influencers. It also warned that retatrutide is still in clinical trials and not approved in the UAE.[13]
How to check a peptide’s status where you live
- Search your regulator’s product database. Examples are FDA’s Drugs@FDA, Health Canada’s Drug Product Database, the TGA’s ARTG and the UK’s MHRA products site. If the peptide isn’t there, it isn’t an authorized medicine.
- Check the prescription schedule. In Australia that is the Poisons Standard. In Canada it is the Prescription Drug List.
- Read recent safety alerts. Most regulators publish advisories that name seized peptides.
- Check sport rules separately if you compete. See peptides on the WADA prohibited list.
Where our information is incomplete
We could not confirm, from an official source, how China, India and Japan treat online “research” peptide sales specifically, or whether New Zealand has issued a peptide-specific warning. The Thailand and UAE entries rely on news reports of official statements rather than the regulators’ own pages. Rules also change quickly, so check the regulator in your country before you act.
This is general information, not legal advice. For your own situation, talk to a pharmacist, doctor or lawyer where you live.
